Print
Email
Print Edition Stories
Aura Biosciences Inc., a Cambridge startup developing nanotechnology for drug delivery, has raised $2.95 million in its second funding round, federal documents show.
Founded in 2009 by CEO Elisabet de los Pinos, a 2010 Mass High Tech Women to Watch honoree, the company’s technology is called Nanosmart. The nanotech platform wraps therapies in a protein nanoparticle that can then deliver the drug to a specific, targeted tumor.
While the filing with the U.S. Securities and Exchange Commission doesn’t name the 23 investors in the round, listed as related persons are directors Lawrence Best of OXO Capital LLC, and Salvador García-Atance of the Spanish not-for-profit foundation Lealtad, among other directors.
According to the Aura Biosciences website, the Nanosmart nanoparticles are designed to mimic viral structures, “engineered for precise targeting, immune system evasion, and efficient cellular uptake.” The company will initially focus on cancer treatments.
Added to a September 2010 fundraise of $1.4 million, Aura Biosciences has now taken in approximately $4.4 million in investment backing since it launched. In February, Aura Biosciences was listed as one of Mass High Tech’s “Startup Watch: Five you should follow” companies.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
